Advanced glycation end-products (AGEs), senescent macroprotein derivatives formed at an accelerated rate in diabetes, are closely associated with vascular calcification in humans. In this study, the hypothesis that AGEs enhance calcification in cultured vascular smooth muscle cells (VSMCs) was tested. Using real-time polymerase chain reaction (PCR) and specific protein assays, it was demonstrated that rat aortic VSMCs incubated with AGEs exhibited an increased expression of the AGE receptor (RAGE) and typical bone proteins, such as osteopontin and alkaline phosphatase.
Introduction
Vascular calcification in atherosclerotic plaques is common in diabetes mellitus, 1 and its presence predicts future cardiovascular events. 2 Despite its clinical relevance, research on the mechanism of mineral deposition in arteries has been limited. Recent research suggests that advanced glycation end-products (AGEs), senescent macroprotein derivatives formed at an accelerated rate in diabetes, are closely correlated with vascular calcification. 3 Since vascular smooth muscle cells (VSMCs) contribute significantly to the active regulation of vascular calcification, 4, 5 this study was designed to investigate whether AGEs can induce the osteoblastic differentiation of rat aortic VSMCs and to study the involvement of the AGE receptor (RAGE).
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PREPARATION OF AGE-BSA
The preparation of AGE-bovine serum albumin (AGE-BSA) was carried out by incubating 20 mg/ml BSA with 50 mmol/l glucose for 90 days as described previously. 6
CELL CULTURE AND IN VITRO CALCIFICATION
The VSMCs were isolated from rat thoracic aortas and maintained as described previously. 7 To induce calcification, cells were switched to Dulbecco's Modified Eagle Medium (DMEM; Gibco ® Invitrogen™, Carlsbad, CA, USA) containing 1% fetal bovine serum and 10 mmol/l β-glycerophosphate (β-GP; Sigma-Aldrich, St Louis, MO, USA) with 50, 100, 200 or 400 µg/ml AGE-BSA or non-glycated BSA for up to 10 days. Cells were harvested for analysis at day 1, day 3, day 6 or day 9. In separate experiments, sub-confluent VSMCs cultured in six-well culture plates were pre-incubated with a neutralizing antibody to RAGE (100 µg/ml) for 2 h. The neutralizing antibody to RAGE was produced in goats immunized with purified, NS0-derived, recombinant rat RAGE (R&D Systems, Minneapolis, MN, USA) and was selected for its ability to block receptor-ligand interaction. Then, AGE-BSA (100 µg/ml) was added to the medium containing 10 mmol/l of β-GP for 24 h prior to measurement of ALP mRNA, osteopontin mRNA or RAGE mRNA, or for 72 h prior to the measurement of calcium content. As a negative control, immunoglobulin G (IgG; R&D Systems) at concentrations equal to the anti-RAGE antibody was used.
QUANTIFICATION OF CALCIUM DEPOSITION
Cells were decalcified with 0.6 M HCl for 24 h and the calcium content of the HCl supernatants was determined by the ocresolphthalein complexone method and normalized for protein content as previously described. 8
ASSAY OF ALP ACTIVITY
Cellular proteins were solubilized with 1% Triton X-100 in 0.9% NaCl and centrifuged at 8000 g for 10 min. Alkaline phosphatase (ALP) activity in cell supernatants was assayed with an ALP Fluorometric (Blue) Assay Kit (Sigma-Aldrich) and normalized to total protein as previously described. 8
REAL-TIME PCR MEASUREMENT OF

MRNA
For measurement of ALP mRNA, osteopontin mRNA and RAGE mRNA, total RNA (2 µg), extracted with TRIzol ® reagent (Invitrogen™, Carlsbad, CA, USA) according to the manufacturer's instructions, was reversetranscribed, and real-time polymerase chain reaction (PCR) was performed with a QuantiTect SYBR Green PCR kit (Takara Biotechnology, Shiga, Japan) using the 2 -∆∆CT method. 9 Primer sets, gene accession numbers and PCR product sizes are listed in Table 1 .
WESTERN BLOT ANALYSIS
The protein levels of RAGE and osteopontin in VSMCs were analysed by Western blot analysis using rat anti-RAGE antibody (R&D Systems) and mouse anti-osteopontin X Ren, H Shao, Q Wei et al. Calcification in VSMCs is enhanced by AGEs antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as previously described. 6 
STATISTICAL ANALYSIS
All data are expressed as mean ± SD. Statistical analysis used SPSS ® version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The significance of the effect of each treatment was determined by analysis of variance followed by the Student-Newman-Keuls test. A P-value of < 0.05 was considered to be statistically significant.
Results
CALCIUM DEPOSITION IN VSMCs
Calcium deposition in rat aortic VSMCs was significantly increased in a time-dependent manner following treatment with 200 µg/ml AGE-BSA compared with non-glycated BSA (day 3, 1.11 ± 0.10 versus 0.73 ± 0.05 µmol/mg, P < 0.05; day 6, 2.18 ± 0.18 versus 1.01 ± 0.13 µmol/mg, P < 0.05; day 9, 3.57 ± 0.24 versus 2.37 ± 0.26 µmol/mg, P < 0.05; n = 3).
Calcium deposition in rat aortic VSMCs after 10 days was also significantly increased in a dose-dependent manner compared with non-glycated BSA. At 10 days, for 100 µg/ml AGE-BSA versus nonglycated BSA calcium deposition significantly increased (2.41 ± 0.35 versus 1.86 ± 0.31 µmol/mg, P < 0.05). Calcium deposition reached a plateau at 200 µg/ml AGE-BSA (3.76 ± 0.34 µmol/mg), with no further significant increase for 400 µg/ml AGE-BSA (3.59 ± 0.27 µmol/mg). Calcium deposition at 200 and 400 µg/ml AGE-BSA was significantly higher than at 100 µg/ml (P < 0.05) and significantly higher than with non-glycated BSA (P < 0.05). The 100 µg/ml concentration of AGE-BSA was, therefore, selected for the rest of the experiments since it was the lowest concentration to give a significant increase in calcium deposition. 
ALP AND OSTEOPONTIN MRNA IN VSMCS
Treatment with AGE-BSA (100 µg/ml) significantly increased ALP activity compared with non-glycated BSA (day 3, 91.1 ± 11.36 versus 40.03 ± 10.39 U/g protein, P < 0.05; day 6, 179.17 ± 11.44 versus 96.40 ± 21.08 U/g protein, P < 0.05; day 9, 246.10 ± 43.57 versus 178.07 ± 20.75 U/g protein, P < 0.05; n = 3) in a timedependent manner.
The expression of ALP and osteopontin mRNA, early and late osteoblastic differentiation markers, respectively, was evaluated. Treatment for 24 h with AGE-BSA (100 µg/ml) resulted in a significant 3.4-fold increase in ALP mRNA (Fig. 1A) and a significant 1.7-fold increase in osteopontin mRNA ( Fig. 2A) compared with non-glycated BSA (P < 0.05). Higher levels of osteopontin protein expression in VSMCs were also induced by AGE-BSA (100 µg/ml) (Fig. 2B ). 
EXPRESSION OF RECEPTOR FOR AGES IN VSMCS
Since it is known that the biological effect of AGEs is mediated at least partly by RAGE, 10 the effect of AGE-BSA (100 µg/ml) on RAGE mRNA and protein expression was evaluated. As shown in Figs 3A and 3B , compared with non-glycated BSA, AGE-BSA (100 µg/ml) increased both mRNA and protein expression of RAGE by at least about 50% at 24 h.
To determine the role of RAGE in AGEinduced calcification in VSMCs, a neutralizing antibody to RAGE was added to the system in separate experiments. The AGE-dependent changes in ALP mRNA (Fig.  1A) and calcium content (Fig. 1B) were partially attenuated by the addition of a neutralizing antibody to RAGE. The increased expression of osteopontin mRNA and protein in response to AGE-BSA were also partially attenuated by a neutralizing (Figs 2A, 2B) . These AGEmediated changes in cells were not prevented by the addition of control immunoglobulin (IgG), indicating that AGE-BSA exerts its stimulatory effect on VSMCs calcification partly through the interaction of AGE with RAGE.
Discussion
The present study demonstrated that, in response to AGEs, rat aortic VSMCs differentiate into cells that exhibit an osteoblast-like phenotype, characterized by the deposition of calcium into the extracellular matrix and the expression of genes normally restricted to mineralized tissue, including osteopontin and ALP. It was also clearly shown that these AGE-dependent changes were partially attenuated by the addition of a neutralizing antibody to RAGE. The results suggest that the AGEs that accumulate in diabetes could elicit the osteoblastic differentiation of VSMCs, thereby contributing to vascular calcification via multiple mechanisms.
Recent studies have demonstrated that vascular calcification is an active and tightly regulated process that resembles 11 Under mineralizing conditions, particularly in diabetes, vascular cells may differentiate into an osteoblast-like phenotype and then produce 'bone' matrix proteins, providing the necessary matrix for subsequent calcification. 11 In the system used in the present study, treatment of VSMCs with elevated AGEs increased the expression of ALP and osteopontin and enhanced calcification in VSMCs, suggesting that AGE may be an alternative inducer of osteoblastic differentiation of VSMCs.
Data from previous studies suggest that the cellular effects of AGEs are largely mediated by RAGE. 10 RAGE is expressed at a very low level in a range of cells, and its expression increases and receptor upregulation is sustained when particular pathological processes intervene. 12 Results from the present study demonstrate that VSMCs expressed an increased amount of RAGE in response to AGEs at both the protein and mRNA level. This is in line with other studies, which demonstrated up-regulation of RAGE by AGEs in osteoblast-like cells 13 and endothelial cells. 14 The interaction of AGEs with RAGE results in the induction of oxidative stress and pro-inflammatory responses, 15 which have been shown to promote vascular calcification. 16 The AGEmediated calcification in the present study appeared to be partly dependent upon the interaction of AGE with RAGE, since these effects could be partially blocked by a neutralizing antibody to RAGE. Thus, it could be suggested that the initial accumulation of AGEs in vascular tissue could, in turn, exacerbate local inflammation and lead to downstream cellular activities that favour cell-mediated vascular calcification by activation of RAGE. Studies are in progress to establish which of these hypotheses best accounts for the effects of AGEs on vascular calcification. Given that diabetic patients exhibit increased levels of AGEs as well as enhanced RAGE expression in the vasculature, blockade of AGE-RAGE signalling might be a therapeutic tool to influence vascular disease in diabetes.
